Expert Interview
A Third Look: Discussing the potential of Incyte's mutCALR-targeted mAb, INCA033989, in patients with Essential Thrombocytopenia and Myelofibrosis
Ticker(s): INCYInstitution: Mount Sinai
- Assistant professor in the Department of Medicine, Division of Hematology & Oncology at the Icahn School of Medicine at Mount Sinai.
- Manages over 20 patients with myelofibrosis
- Director of the Tisch Cancer Institute Hematological Malignancies Tissue Bank and the NCI funded P01 funded Myeloproliferative Neoplasms-Research Consortium Tissue Bank; Research focused on elucidating the mechanisms driving the formation and progression of myeloid malignancies
Where do you see the unmet need in myelofibrosis and ET now?
Added By: wilson_adminIn your opinion how strong is the data on INCA033989?
Added By: wilson_adminWhat other promising MoA's are under development for MF/ET?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Dec 29, 2025
- Call Time
- 10:30 AM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
